206 related articles for article (PubMed ID: 38145979)
1. Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis.
Yamaguchi A; Saito Y; Takekuma Y; Sugawara M
Support Care Cancer; 2023 Dec; 32(1):58. PubMed ID: 38145979
[TBL] [Abstract][Full Text] [Related]
2. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.
Popovic M; Warr DG; Deangelis C; Tsao M; Chan KK; Poon M; Yip C; Pulenzas N; Lam H; Zhang L; Chow E
Support Care Cancer; 2014 Jun; 22(6):1685-97. PubMed ID: 24590374
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
[TBL] [Abstract][Full Text] [Related]
5. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
6. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Opin Pharmacother; 2014 Dec; 15(17):2599-608. PubMed ID: 25323946
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults.
Likun Z; Xiang J; Yi B; Xin D; Tao ZL
Oncologist; 2011; 16(2):207-16. PubMed ID: 21282670
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
9. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
Shirley M
Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
[TBL] [Abstract][Full Text] [Related]
11. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.
Botrel TE; Clark OA; Clark L; Paladini L; Faleiros E; Pegoretti B
Support Care Cancer; 2011 Jun; 19(6):823-32. PubMed ID: 20495832
[TBL] [Abstract][Full Text] [Related]
13. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
14. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
Celio L; Agustoni F; Testa I; Dotti K; de Braud F
Tumori; 2012; 98(3):279-86. PubMed ID: 22825501
[TBL] [Abstract][Full Text] [Related]
15. Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study.
Lin SJ; Hatoum HT; Buchner D; Cox D; Balu S
BMC Health Serv Res; 2012 Jul; 12():215. PubMed ID: 22823909
[TBL] [Abstract][Full Text] [Related]
16. Should palonosetron be a preferred 5-HT
Chow R; Warr DG; Navari RM; Tsao M; Popovic M; Chiu L; Milakovic M; Lam H; DeAngelis C
Support Care Cancer; 2018 Aug; 26(8):2519-2549. PubMed ID: 29796708
[TBL] [Abstract][Full Text] [Related]
17. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
19. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
Navari RM
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2738-46. PubMed ID: 25838122
[TBL] [Abstract][Full Text] [Related]
20. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]